Noone 2014.

Methods	Parallel trial of milnacipran versus placebo
Participants	Inclusion criteria: aged 18‐50 years diagnosis of ASD according to DSM‐IV‐R IQ > 70 Exclusion criteria: pregnant deemed by comprehensive psychiatric interview to have a significant risk of suicide "comorbid medical, neurological and psychiatric illnesses with the exception of ADHD and OCD were excluded" Location/setting: USA Sample size: 10 in total Number of withdrawals/dropouts: not reported Gender: not reported Mean age: 19‐41 years IQ: > 70 Baseline ABC‐I or other BoC: not reported Concomitant medications: not reported, although comorbid neurological, psychiatric and medical condition excluded except for ADHD or OCD History of previous medications: not reported
Interventions	Intervention (milnacipran) for 12 weeks: participants were given a titrated dose of milnacipran increasing to a maximum of 100 mg a day over the 12‐week study period. Dosing was based on a fixed schedule that was monitored using a side‐effect profile. Comparator (placebo) for 12 weeks: participants were given placebo tablets at dosing corresponding to the fixed schedule between 12.5 mg and 100 mg.
Outcomes	Primary outcomes: ABC‐I (Aman 1985) (not reported in paper or clinicaltrials.gov website) Secondary outcomes: none reported Timing of outcome assessments: twice‐weekly
Notes	Study start date: February 2011 Study end date: July 2014 Source of funding: "funded by an investigator initiated grant from Forest Pharmaceuticals, Inc" Conflicts of interest: none declared